Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31678219 | 0.94 | BRD4 (0.38) | LTA4HDPP4DPP8DPP9BRD4 | |
| SCHEMBL2176405 | 0.80 | DPP4 (0.43) | LTA4HDPP4DPP8DPP9BRD4 | |
| SCHEMBL19271810 | 0.78 | NOS3 (0.43) | LTA4HDPP4DPP8DPP9CYP2D6 | |
| SCHEMBL6103837 | 0.78 | NOS3 (0.43) | LTA4HDPP4DPP8DPP9CYP2D6 | |
| SCHEMBL12443431 | 0.77 | HSD11B1 (0.35) | LTA4HALDH1A1MAPTL3MBTL1 | |
| SCHEMBL10427141 | 0.77 | NOS3 (0.42) | LTA4HDPP4DPP8DPP9CYP2D6 | |
| SCHEMBL867932 | 0.77 | NOS3 (0.42) | LTA4HDPP4DPP8DPP9CYP2D6 | |
| SCHEMBL868782 | 0.77 | NOS3 (0.42) | LTA4HDPP4DPP8DPP9CYP2D6 | |
| SCHEMBL8031217 | 0.77 | NOS3 (0.42) | LTA4HDPP4DPP8DPP9CYP2D6 | |
| SCHEMBL6088399 | 0.77 | NOS3 (0.42) | LTA4HDPP4DPP8DPP9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | LTA4H 634/4885DPP4 803/4885DPP8 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.